Teduglutide for the treatment of short bowel syndrome

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 6, 2011, Pages 665-678

  Vipperla, Kishore ^a   O'Keefe, Stephen J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

glucagon like peptide 2; intestinal failure; parenteral nutrition; short bowel syndrome; teduglutide

Indexed keywords

GATTEX; GLUCAGON LIKE PEPTIDE 2; REVESTIVE; TEDUGLUTIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICLE; ASTHENIA; CARDIOTOXICITY; COLON TUMOR; COMA; CONSTIPATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEMORRHOID HEMORRHAGE; HUMAN; HYPERSOMNIA; INJECTION SITE PAIN; INTESTINE OBSTRUCTION; INTESTINE STENOSIS; NAUSEA; NEUROTOXICITY; PANCREATITIS; PEPTIDE ANALYSIS; PHARMACODYNAMICS; RHINOPHARYNGITIS; SHORT BOWEL SYNDROME; SINGLE DRUG DOSE; SMALL INTESTINE OBSTRUCTION; VOMITING;

AMINO ACID SEQUENCE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; MOLECULAR SEQUENCE DATA; PARENTERAL NUTRITION; PEPTIDES; SHORT BOWEL SYNDROME; TREATMENT OUTCOME;

EID: 80155182132     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.82     Document Type: Article

References (102)

1. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin. Gastroenterol. Hepatol. 4(1), 6-10 (2006).
2. Wales PW, Christison-Lagay ER. Short bowel syndrome: epidemiology and etiology. Semin. Pediatr. Surg. 19(1), 3-9 (2010).
3. Carbonnel F, Cosnes J, Chevret S et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN J. Parenter. Enteral Nutr. 20(4), 275-280 (1996).
4. Drozdowski L, Thomson AB. Intestinal mucosal adaptation. World J. Gastroenterol. 12(29), 4614-4627 (2006).
5. Longshore SW, Wakeman D, McMellen M, Warner BW. Bowel resection induced intestinal adaptation: progress from bench to bedside. Minerva Pediatr. 61(3), 239-251 (2009).
6. Crenn P, Morin MC, Joly F, Penven S, Thuillier F, Messing B. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. Gut 53(9), 1279-1286 (2004).
7. Mullady DK, O'Keefe SJD. Treatment of intestinal failure: home parenteral nutrition. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(9), 492-504 (2006).
8. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 124(4), 1111-1134 (2003).
9. Staun M, Pironi L, Bozzetti F et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin. Nutr. 28(4), 467-479 (2009).
10. Shils ME. The advent of home parenteral nutrition support. Annu. Rev. Nutr. 30(1), 1-12 (2010).
11. Jeejeebhoy KN, Langer B, Tsallas G, Chu RC, Kuksis A, Anderson GH. Total parenteral nutrition at home: studies in patients surviving 4 months to 5 years. Gastroenterology 71(6), 943-953 (1976).
12. Buchman AL, Moukarzel A, Goodson B et al. Catheter-related infections associated with home parenteral nutrition and predictive factors for the need for catheter removal in their treatment. JPEN J. Parenter. Enteral Nutr. 18(4), 297-302 (1994).
13. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann. Intern. Med. 132(7), 525-532 (2000).
14. Goulet O, Joly F, Corriol O, Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. Curr. Opin. Organ Transplant. 14(3), 256-261 (2009).
15. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 130(2 Suppl. 1), S70-S77 (2006).
16. Lauverjat M, Hadj Aissa A, Vanhems P, Bouletreau P, Fouque D, Chambrier C. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin. Nutr. 25(1), 75-81 (2006).
17. O'Keefe SJ, Burnes JU, Thompson RL. Recurrent sepsis in home parenteral nutrition patients: an analysis of risk factors. JPEN J. Parenter. Enteral Nutr. 18(3), 256-263 (1994).
18. Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin. Nutr. 25(4), 543-553 (2006).
19. Winkler MF, Hagan E, Wetle T, Smith C, Maillet JO, Touger-Decker R. An exploration of quality of life and the experience of living with home parenteral nutrition. JPEN J. Parenter. Enteral Nutr. 34(4), 395-407 (2010).
20. Modi BP, Javid PJ, Jaksic T et al. First report of the international serial transverse enteroplasty data registry: indications, efficacy, and complications. J. Am. Coll. Surg. 204(3), 365-371 (2007).
21. Misiakos EP, Macheras A, Kapetanakis T, Liakakos T. Short bowel syndrome: current medical and surgical trends. J. Clin. Gastroenterol. 41(1), 5-18 (2007).
22. O'Keefe SJ, Emerling M, Koritsky D et al. Nutrition and quality of life following small intestinal transplantation. Am. J. Gastroenterol. 102(5), 1093-1100 (2007).
23. Abu-Elmagd KM, Costa G, Bond GJ et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann. Surg. 250(4), 567-581 (2009).
24. O'Keefe SJ. Candidacy for intestinal transplantation. Am. J. Gastroenterol. 101(7), 1644-1646 (2006).
25. Jeejeebhoy KN. Treatment of intestinal failure: transplantation or home parenteral nutrition? Gastroenterology 135(1), 303-305 (2008).North American Home Parenteral and Enteral Nutrition Registry. Annual Reports 1992. Oley Foundation, Albany, NY, USA, 12208 (1994).
26. Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology 130(2 Suppl. 1), S52-S59 (2006).
27. Viall CD. Home parenteral nutrition finances. In:Clinical Nutrition: Parenteral Nutrition (3rd Edition).Rombeau JL, Rolandelli RH (Eds).WB Saunders, Philadelphia, PA, USA, 512-528 (2001).
28. Spencer AU, Kovacevich D, McKinney- Barnett M et al. Pediatric short-bowel syndrome: the cost of comprehensive care. Am. J. Clin. Nutr. 88(6), 1552-1559 (2008).
29. Messing B, Crenn P, Beau P, Boutron- Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 117(5), 1043-1050 (1999).
30. Scolapio JS, Fleming CR, Kelly DG, Wick DM, Zinsmeister AR. Survival of home parenteral nutrition-treated patients: 20 years of experience at the Mayo Clinic. Mayo Clin. Proc. 74(3), 217-222 (1999).
31. Jeppesen PB, Hartmann B, Thulesen J et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120(4), 806-815 (2001).
32. O'Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J. Parenter. Enteral Nutr. 18(1), 26-34 (1994).
33. O'Keefe SJ, Haymond MW, Bennet WM, Oswald B, Nelson DK, Shorter RG. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology 107(2), 379-388 (1994).
34. Byrne TA, Wilmore DW, Iyer K et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann. Surg. 242(5), 655-661 (2005).
35. Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst. Rev. 16(6), CD006321 (2010).
36. Pereira PM, Bines JE. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome. J. Gastroenterol. Hepatol. 21(6), 932-940 (2006).
37. Jeppesen PB. Growth factors in short-bowel syndrome patients. Gastroenterol. Clin. North Am. 36(1), 109-121 (2007).
38. Yang H, Teitelbaum DH. Novel agents in the treatment of intestinal failure: humoral factors. Gastroenterology 130(2 Suppl. 1), S117-S121 (2006).
39. Bulut K, Pennartz C, Felderbauer P et al. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur. J. Pharmacol. 578(2-3), 279-285 (2008).
40. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122(2), 531-544 (2002).
41. Sinclair EM, Drucker DJ. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology 20, 357-365 (2005).
42. Sigalet DL, Lam V, Boctor D. The assessment, and glucagon-like peptide-2 modulation, of intestinal absorption and function. Semin. Pediatr. Surg. 19(1), 44-49 (2010).
43. Bloom SR. An enteroglucagon tumour. Gut 13(7), 520-523 (1972).
44. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 12(10), 773-782 (1971).
45. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl Acad. Sci. USA 93(15), 7911-7916 (1996).
46. Ghatei MA, Goodlad RA, Taheri S et al. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig. Dis. Sci. 46(6), 1255-1263 (2001).
47. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 45(4), 559-563 (1999).
48. Jeppesen PB, Hartmann B, Thulesen J et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 47(3), 370-376 (2000).
49. Martin GR, Wallace LE, Hartmann B et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 288(3), 23 (2005).
50. Nightingale JM, Lennard-Jones JE. The short bowel syndrome: what's new and old? Dig. Dis. 11(1), 12-31 (1993).
51. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117(1), 99-105 (1999).
52. Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(6), 1 (2008).
53. Rowland KJ, Brubaker PL. Life in the crypt: a role for glucagon-like peptide-2? Mol. Cell Endocrinol. 288(1-2), 63-70 (2008).
54. Arda-Pirincci P, Bolkent S. The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-a/ actinomycin D. Mol. Cell Biochem. 350(1-2), 13-27 (2011).
55. Rowland KJ, Brubaker PL. The 'cryptic' mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol. 301(1), G1-G8 (2011).
56. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand. J. Gastroenterol. 39(4), 353-358 (2004).
57. Meier JJ, Nauck MA, Pott A et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130(1), 44-54 (2006).
58. Gottschalck IB, Jeppesen PB, Hartmann B, Holst JJ, Henriksen DB. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand. J. Gastroenterol. 43(11), 1304-1310 (2008).
59. Henriksen DB, Alexandersen P, Hartmann B et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45(5), 833-842 (2009).
60. Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul. Pept. 168(1-3), 32-38 (2011).
61. Hadjiyanni I, Li KK, Drucker DJ. Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of Type 1 diabetes in the nonobese diabetic mouse. Endocrinology 150(2), 592-599 (2009).
62. Estall JL, Drucker DJ. Glucagon-like Peptide-2. Annu. Rev. Nutr. 26, 391-411 (2006).
63. Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21(6), 619-670 (2000).
64. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am. J. Physiol. Endocrinol. Metab. 293(2), 24 (2007).
65. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul. Pept. 124(1-3), 105-112 (2005).
66. Rocha FG, Shen KR, Jasleen J et al. Glucagon-like peptide-2: divergent signaling pathways. J. Surg. Res. 121(1), 5-12 (2004).
67. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 81(11), 1005-1012 (2003).
68. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 8(3-4), 179-188 (2002).
69. Yusta B, Boushey RP, Drucker DJ. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J. Biol. Chem. 275(45), 35345-35352 (2000).
70. Rowland KJ, Brubaker PL. The 'cryptic' mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol. 301(1), 28 (2011).
71. Yusta B, Huang L, Munroe D et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119(3), 744-755 (2000).
72. Drucker DJ, Shi Q, Crivici A et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15(7), 673-677 (1997).
73. DaCambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker DJ, Brubaker PL. Structural determinants for activity of glucagon-like peptide-2. Biochemistry 39(30), 8888-8894 (2000).
74. Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am. J. Physiol. Endocrinol. Metab. 278(1), E134-E139 (2000).
75. Marier JF, Beliveau M, Mouksassi MS et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J. Clin. Pharmacol. 48(11), 1289-1299 (2008).
76. Jeppesen PB, Sanguinetti EL, Buchman A et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54(9), 1224-1231 (2005).
77. Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am. J. Physiol. 273(6 Pt 1), G1252-G1262 (1997).
78. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. 275(5 Pt 1), G911-G921 (1998).
79. Yang ZJ BC, Urlando C, Demchyshyn LL. The intestinotrophic properties of ALX-0600, a glucagon-like peptide-2 analogue. Gastroenterology 118(4 Suppl. 2) (2000) (Abstract 2880).
80. Sigalet DL Martin GR. Harmonal therapy for short bowel syndrome. J. Pediatr. Surg. 35(2), 360-363 (2000).
81. Tappenden KA. Teduglutide is a potent stimulul's for intestinal adaptation in a neonatal piglet model of short bowel syndrome accompanied by parenteral nutrition therapy. Digestive Disease Week, Washington DC, USA, 20-24 May 2007 (Abstract S2201).
82. Marier JF, Mouksassi MS, Gosselin NH, Beliveau M, Cyran J, Wallens J. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. J. Clin. Pharmacol. 50(1), 36-49 (2010).
83. Metcalfe AJ, Oliver SD, Dietrich J. An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects [abstract 4973]. Gastroenterology 118(4 Suppl. 2 pt 2), A1072 (2000).
84. Tappenden KA, Bartholome AL, Demchyshyn L et al. ALX-0600, a glucagon-like peptide-2 (GLP-2) analog, enhances intestinal structure and function in patients with short bowel syndrome. Gastroenterology 122, A192 (2002).
85. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 11, 11 (2011).
86. Palle B. Jeppesen MP, Douglas L et al. Teduglutide, a novel analogue of glucagon-like peptide 2 (GLP-2), is effective and safe in reducing parenteral support volume in short bowel syndrome-intestinal failure subjects: results from a 24-week, placebo-controlled Phase 3 trial (STEPS) Gastroenterology 140(5, Suppl. 1), S146 (2011).
87. Jeppesen PB, Lund P, Gottschalck IB et al. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol. Res. Pract. 425759, 5 (2009).
88. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res. 68(19), 7897-7904 (2008).
89. Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol. Endocrinol. 19(2), 459-473 (2005).
90. Thulesen J, Hartmann B, Hare KJ et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53(8), 1145-1150 (2004).
91. Garrison AP, Dekaney CM, von Allmen DC, Lund PK, Henning SJ, Helmrath MA. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am. J. Physiol. Gastrointest. Liver Physiol. 296(3), 31 (2009).
92. Kaji T, Tanaka H, Redstone H, Wallace LE, Holst JJ, Sigalet DL. Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection. J. Surg. Res. 152(2), 271-280 (2009).
93. Washizawa N, Gu LH, Gu L, Openo KP, Jones DP, Ziegler TR. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. JPEN J. Parenter. Enteral Nutr. 28(6), 399-409 (2004).
94. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 277(5 Pt 1), E937-E947 (1999).
95. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 61(2), 687-693 (2001).
96. Torres S, Thim L, Milliat F et al. Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat. Int. J. Radiat. Oncol. Biol. Phys. 69(5), 1563-1571 (2007).
97. Zhang W, Zhu W, Zhang J, Li N, Li J. Protective effects of glucagon-like peptide 2 on intestinal ischemia-reperfusion rats. Microsurgery 28(4), 285-290 (2008).
98. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif. 37(6), 385-400 (2004).
99. Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm. Bowel Dis. 17(1), 410-422 (2011).
100. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm. Bowel Dis. 16(6), 962-973 (2010).
101. Mouksassi MS, Marier JF, Cyran J, Vinks AA. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin. Pharmacol. Ther. 86(6), 667-671 (2009).
102. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metabol. 1(1), 22-31 (2005).